Laurie D Snyder,^1,2 Christopher Mosher,² Colin H Holtze,³ Lisa H Lancaster,⁴ Kevin R Flaherty,³ Imre Noth,⁵ Megan L Neely,^1,2 Anne S Hellkamp,^1,2 Shaun Bender,⁶ Craig S Conoscenti,⁶ Joao A de Andrade,⁴ Timothy PM Whelan⁷ on behalf of the IPF-PRO Registry investigators

¹Duke Clinical Research Institute, Durham, North Carolina, USA; ²Duke University Medical Center, Durham, North Carolina, USA; ³University of Michigan, Ann Arbor, Michigan, USA; ⁴Vanderbilt University Medical Center, Nashville, Tennessee, USA; ⁵Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA; ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; ⁷Medical University of South Carolina, Charleston, South Carolina, USA.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis.¹
Delays in the diagnosis of IPF have been reported,^2–4 but patient characteristics associated with diagnostic delays are not well described.
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry (NCT01915511) is an observational registry of patients with IPF involving over 40 sites across the US.⁵